Aquinox Pharmaceuticals Inc (AQXP)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Aquinox Pharmaceuticals Inc (AQXP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8010846
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月20日
◆ページ数:42
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Aquinox Pharmaceuticals Inc (Aquinox) is a clinical-stage pharmaceutical company which develops targeted therapeutics in the areas of inflammation and immuno-oncology. The company’s lead product candidate AQX-1125, is a SHIP1 activator which is a natural modulator of the PI3K pathway to reduce inflammatory diseases. It undertakes clinical trials of several drugs for the treatment of chronic obstructive pulmonary disease, bladder pain syndrome interstitial cystitis, allergic asthma and atopic dermatitis, among others. Aquinox’s discovery platform enables in discovering new drug candidates that target SHIP1 to modulate reactive immune cells while minimizing their toxicity to normal cells. The company works in collaboration with British Columbia Cancer Agency and University of British Columbia. Aquinox is headquartered in Vancouver, British Columbia, Canada.

Aquinox Pharmaceuticals Inc (AQXP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Aquinox Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Aquinox Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Aquinox Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Aquinox Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Aquinox Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Aquinox Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Aquinox Pharma Raises US$18 Million In Series C Financing 10
Aquinox Pharma Raises USD3.5 Million in Venture Financing 11
Aquinox Pharma Raises USD4.7 Million in Venture Financing 12
Equity Offering 13
Aquinox Pharma Plans to Raise up to USD171.4 Million in Public Offering of Shares 13
Aquinox Pharma Raises USD57.7 Million in Public Offering of Shares 14
Aquinox Pharma Raises USD98 Million in Public Offering of Shares 16
Aquinox Pharma to Raise USD25 Million in Public Offering of Shares 18
Aquinox Pharma Completes IPO For US$53 Million 19
Aquinox Pharmaceuticals Inc – Key Competitors 21
Aquinox Pharmaceuticals Inc – Key Employees 22
Aquinox Pharmaceuticals Inc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Aug 08, 2017: Aquinox Pharmaceuticals Announces Second Quarter 2017 Financial Results 24
May 09, 2017: Aquinox Pharmaceuticals Announces First Quarter 2017 Financial Results 26
Mar 09, 2017: Aquinox Pharmaceuticals Announces Year End 2016 Financial Results 27
Nov 09, 2016: Aquinox Pharmaceuticals Announces Third Quarter 2016 Financial Results 29
Aug 04, 2016: Aquinox Pharmaceuticals Announces Second Quarter 2016 Financial Results 30
Mar 14, 2016: Aquinox Pharmaceuticals Announces Year End 2015 Financial Results 32
Corporate Communications 34
Mar 27, 2017: Aquinox Announces Appointment of Dr. Kelvin Neu and Dr. Richard Levy to Board of Directors 34
Product News 35
11/22/2016: Aquinox and the University of Southampton Announce Presentation of Abstract at American Society of Hematology Annual Meeting 35
10/03/2016: Aquinox Announces Appointment of Dr. Barbara Troupin as Chief Medical Officer 36
05/25/2016: Aquinox Announces Executive Appointments 37
05/10/2016: Aquinox Pharmaceuticals Announces First Quarter 2016 Financial Results 38
01/11/2016: Aquinox Announces Update on Development Program for AQX-1125 Following Meeting With FDA 40
Clinical Trials 41
Sep 06, 2016: Aquinox Pharmaceuticals Initiates Patient Dosing in LEADERSHIP 301 Phase 3 Clinical Trial of AQX-1125 in Interstitial Cystitis/Bladder Pain Syndrome 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42

List of Tables
Aquinox Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Aquinox Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Aquinox Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Aquinox Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Aquinox Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Aquinox Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Aquinox Pharma Raises US$18 Million In Series C Financing 10
Aquinox Pharma Raises USD3.5 Million in Venture Financing 11
Aquinox Pharma Raises USD4.7 Million in Venture Financing 12
Aquinox Pharma Plans to Raise up to USD171.4 Million in Public Offering of Shares 13
Aquinox Pharma Raises USD57.7 Million in Public Offering of Shares 14
Aquinox Pharma Raises USD98 Million in Public Offering of Shares 16
Aquinox Pharma to Raise USD25 Million in Public Offering of Shares 18
Aquinox Pharma Completes IPO For US$53 Million 19
Aquinox Pharmaceuticals Inc, Key Competitors 21
Aquinox Pharmaceuticals Inc, Key Employees 22
Aquinox Pharmaceuticals Inc, Other Locations 23

★海外企業調査レポート[Aquinox Pharmaceuticals Inc (AQXP)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Greenply Industries Ltd:企業の戦略・SWOT・財務情報
    Greenply Industries Ltd - Strategy, SWOT and Corporate Finance Report Summary Greenply Industries Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • ConforMIS Inc (CFMS):医療機器:M&Aディール及び事業提携情報
    Summary ConforMIS Inc (ConforMIS) is a medical technology company that manufactures, develops, and markets joint replacement implants. The company’s knee replacement implant products include iTotal CR a cruciate-retaining product, iTotal PS a posterior cruciate ligament substituting product, and iDu …
  • Orchids Paper Products Co (TIS):企業の財務・戦略的SWOT分析
    Orchids Paper Products Co (TIS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Handok Inc (002390)-医療機器分野:企業M&A・提携分析
    Summary Handok Inc (Handok), formerly known as Handok Pharmaceuticals Co Ltd, is a pharmaceutical and health care company which develops, manufactures and distributes healthcare solutions. The company develops and provides pharmaceutical products including prescription drugs, OTC drugs, medical devi …
  • PT. Indonesia Power:企業の戦略的SWOT分析
    PT. Indonesia Power - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • BASF Corp:企業のM&A・事業提携・投資動向
    BASF Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BASF Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Maintel Holdings Plc (MAI):企業の財務・戦略的SWOT分析
    Summary Maintel Holdings Plc (Maintel) is a telecommunication service provider that supports voice and data equipments. The company provides collaborations, customer experience and optimization, connectivity, security and networking, mobile professional and transformation services and managed servic …
  • H. Lundbeck A/S:企業のM&A・事業提携・投資動向
    H. Lundbeck A/S - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's H. Lundbeck A/S Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Teledyne Technologies Incorporated (TDY):石油・ガス:M&Aディール及び事業提携情報
    Summary Teledyne Technologies Incorporated (Teledyne) is a provider of enabling technologies for industrial growth markets. The company’s product portfolio comprises digital imaging sensors, cameras and systems, infrared and X-ray spectra, monitoring and control instrumentation. It also offers elect …
  • HESTA Super Fund:企業の戦略的SWOT分析
    HESTA Super Fund - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Southern Company Gas:石油・ガス:M&Aディール及び事業提携情報
    Summary Southern Company Gas (SCG), formerly AGL Resources Inc., is an energy services holding company It operates through natural gas distribution, retail operations, wholesale services and midstream. The company serves utility customers through its regulated distribution subsidiaries in the states …
  • Meiji Co Ltd:企業の戦略・SWOT・財務情報
    Meiji Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Meiji Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Mayo Clinic:製薬・医療:M&Aディール及び事業提携情報
    Summary Mayo Clinic (Mayo) is a not-for-profit medical practice and medical research organization. It provides comprehensive medical facilities and programs related to patient care services, research and medical education. It offers specialized medical care with medical departments and centers in mo …
  • Clinigen Group Plc (CLIN):企業の財務・戦略的SWOT分析
    Summary Clinigen Group Plc (Clinigen Group) operates as a pharmaceutical and services company that provides access to clinical trials, medicines, unlicensed and commercial supply. The company acquires and licenses essential commercial medicines such as foscavir, cardioxane, ethyol, savene and vibati …
  • Revenio Group Oyj (REG1V):企業の財務・戦略的SWOT分析
    Revenio Group Oyj (REG1V) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • PT. Indonesia Power:企業の戦略的SWOT分析
    PT. Indonesia Power - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • China Southern Airlines Company Limited:企業のM&A・事業提携・投資動向
    China Southern Airlines Company Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's China Southern Airlines Company Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed re …
  • Mercuria Energy Group Ltd:企業のM&A・事業提携・投資動向
    Mercuria Energy Group Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mercuria Energy Group Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • Heron Resources Ltd:企業の戦略・SWOT・財務分析
    Heron Resources Ltd - Strategy, SWOT and Corporate Finance Report Summary Heron Resources Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Embotelladora Andina SA (ANDINA-B):企業の財務・戦略的SWOT分析
    Embotelladora Andina SA (ANDINA-B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆